Nevertheless, given other highly significant results obtained within the latter subgroup, it is reasonable to conclude that multiplicity adjustments would not have affected the study conclusions.
← all excerpts
Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial.
1
—
—